RNAZ.NASDAQTranscode Therapeutics, INC
S-1/A: TransCode Therapeutics Announces Common Stock and Warrant Offering to Bolster Oncology Pipeline
Sentiment:
S-1/A Filing
TransCode Therapeutics is offering shares and warrants to fund its oncology platform, including its lead candidate TTX-MC138, while facing Nasdaq compliance challenges.
Capital raiseTransCode Therapeutics is offering up to 3,472,222 shares of common stock together with common stock purchase warrants to purchase up to 6,944,444 shares of common stock, or the common stock purchase warrants.Each share of our common stock, or a pre-funded warrant in lieu thereof, is being sold together with two common stock purchase warrants.Each common stock purchase warrant entitles the holder to purchase one share of our common stock per warrant.We are also offering to each purchaser whose purchase of shares of our common stock in this offering would otherwise result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the holder, 9.99%) of our outstanding shares of common stock immediately following consummation of this offering, the opportunity to purchase, if the purchaser so chooses, pre-funded warrants to purchase shares of common stock, or the pre-funded warrants, in lieu of shares of common stock.
Worse than expectedThe company is not in compliance with the stockholders equity requirement for continued listing of its common stock on the Nasdaq Capital Market.The company has incurred significant losses since inception, and expects to incur losses over the next several years and may not be able to achieve or sustain revenues or profitability in the future.The company has identified conditions and events that raise substantial doubt about its ability to continue operations in the near-term and its independent registered public accounting firm has expressed substantial doubt about its ability to continue as a going concern.
Summary
- TransCode Therapeutics is offering up to 3,472,222 shares of common stock along with warrants to purchase up to 6,944,444 shares.
- The offering also includes pre-funded warrants as an alternative for purchasers who would exceed beneficial ownership limits.
- Each share or pre-funded warrant is paired with two common stock purchase warrants, exercisable immediately at a price to be determined, expiring in 3.5 years.
- The company intends to use the net proceeds for product development, including clinical trials for TTX-MC138, and for general corporate purposes.
- The offering is expected to close around January 2024, but may be terminated earlier at the company's discretion.
- TransCode is currently not in compliance with Nasdaq's stockholders' equity requirement and faces potential delisting.
- The company is an emerging growth company and a smaller reporting company, allowing for reduced disclosure requirements.
Sentiment
Score: 4
Explanation: The document presents a mixed sentiment. While it highlights positive preclinical results and potential milestones, it also acknowledges significant financial challenges, including the risk of delisting from Nasdaq and the need for additional capital. The overall tone is cautiously optimistic but tempered by the company's financial situation.
Positives
- The company has a novel therapeutic agent (TTX-MC138) that relies on specific eradication of metastatic tumor cells.
- Preclinical studies have shown that TTX-MC138 mediates significant miR-10b inhibition in vivo, eliciting a marked and durable regression of lymph node and distant metastases in mouse models of breast cancer with no evidence of systemic toxicity.
- The company has received Orphan Drug Designation from the FDA for TTX-MC138 in pancreatic cancer.
- The company has a modular design toolbox for developing therapeutic candidates designed to attack specific disease-causing RNA targets based on the phenomenon of genetic complementarity.
Negatives
- The company is not in compliance with the stockholders equity requirement for continued listing of its common stock on the Nasdaq Capital Market.
- The company has incurred significant losses since inception, and expects to incur losses over the next several years and may not be able to achieve or sustain revenues or profitability in the future.
- The company has identified conditions and events that raise substantial doubt about its ability to continue operations in the near-term and its independent registered public accounting firm has expressed substantial doubt about its ability to continue as a going concern.
Risks
- The company's business is highly dependent on the success of TTX-MC138, its lead therapeutic candidate which is at the early stages of development.
- The company faces substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than the company does.
- The price of the company's common stock may be volatile and fluctuate substantially, which could result in substantial losses for purchasers of the company's common stock.
- The company has broad discretion in the use of the net proceeds from this offering and may not use them effectively.
- The company has identified material weaknesses in its internal control over financial reporting. If the company is unable to remediate these material weaknesses, or if it identifies additional material weaknesses in the future or otherwise fails to maintain an effective system of internal controls, it may not be able to accurately or timely report its financial condition or results of operations, which may adversely affect its business and the trading price of its common stock.
Future Outlook
The company plans to file an IND application with FDA in the first quarter of 2024 seeking approval to conduct a Phase 1/II clinical trial with TTX-MC138 in patients with advanced solid tumors.
Industry Context
The global metastatic cancer treatment market is expected to reach $136.9 billion by 2032, highlighting the significant unmet medical need and commercial opportunity.
Comparison to Industry Standards
- The document mentions competitors like Ionis, Moderna, and Alnylam, which are also developing RNA therapeutics, but TransCode believes its delivery systems are superior for targeting tumors and metastases.
- The document references Feridex and Feraheme, iron oxide nanoparticles used in imaging and iron deficiency anemia, as benchmarks for the safety and tolerability of TransCode's TTX platform.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| President, Chief Executive Officer and Director | Michael Dudley | Thomas A. Fitzgerald | January 13, 2024 | Restructuring |
| Executive Chairman | NA | Philippe Calais | January 13, 2024 | Restructuring |
Stakeholder Impact
- Shareholders face potential dilution and the risk of losing their investment if the company is delisted or undergoes restructuring.
- Employees have been affected by layoffs as part of the company's restructuring efforts.
- Patients may benefit from the development of new cancer treatments, but clinical trials are still in early stages.
- Suppliers and creditors may be impacted by the company's financial instability and potential restructuring.
Next Steps
- The company may enroll additional patients in its Phase 0 trial.
- The company plans to submit the IND application for a Phase I clinical trial in the first quarter of 2024.
- The company anticipates completion of assay development to measure miR-10b in blood samples from patients in the Phase I trial.
- The company has ongoing discussions with potential strategic partners and hopes to complete a partnering agreement sometime in 2024.
- The company may initiate manufacturing activities to support IND-enabling studies for other preclinical assets if capital is available in 2024.
- The company may file for European Orphan Drug Designation status for TTX-MC138 in pancreatic cancer in 2024.
Key Dates
| Date | Description |
|---|---|
| January 11, 2016 | TransCode Therapeutics, Inc. was incorporated. |
| March 2010 | The Affordable Care Act was passed, substantially changing healthcare financing. |
| April 2012 | The Jumpstart Our Business Startups Act of 2012 (JOBS Act) was enacted. |
| May 16, 2023 | TransCode received notification from Nasdaq regarding non-compliance with stockholders' equity requirement. |
| May 23, 2023 | TransCode effected a 1-for-20 reverse stock split. |
| June 30, 2023 | TransCode submitted a compliance plan to Nasdaq. |
| July 26, 2023 | TransCode received a Delisting Determination Letter from Nasdaq. |
| August 2, 2023 | TransCode submitted a request for a hearing to Nasdaq. |
| October 5, 2023 | The Nasdaq Hearings Panel held a hearing regarding TransCode's compliance. |
| October 26, 2023 | TransCode received a letter from the Nasdaq Hearings Panel granting an extension to continue its listing on Nasdaq until January 22, 2024. |
| January 16, 2024 | TransCode effected a 1-for-40 reverse stock split. |
| January 22, 2024 | Deadline for TransCode to provide an update to the Nasdaq Hearings Panel on how it will demonstrate long-term compliance with the Equity Rule. |
| May 6, 2024 | Compliance Date for TransCode to regain compliance with the Minimum Bid Price Requirement. |
| December 31, 2026 | Latest date TransCode can be an emerging growth company. |
Keywords
TTX-MC138, warrants, pre-funded, oncology, metastatic, TransCode, RNA, clinical, offering, therapy
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.